vTv jumps after FDA lifts clinical hold on diabetes therapy
Shares of drug developer vTv Therapeutics VTVT.O rise 19.2% to $17.70, their biggest one-day percentage win in more than one year
Co says U.S. FDA has lifted clinical hold on development of cadisegliatin, an oral adjunctive therapy to insulin therapy for treatment of type 1 diabetes
Co plans to resume its late-stage trial for the therapy after submitting protocol amendment to shorten trial from 12 to 6 months
Up to last close, stock down 12.9% in last 12 months
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

Nvidia Shares Hit Record High, Market Cap Tops $526 Trillion, How Much Higher Can It Go Amid AI Capex Boom?

Tradingkey







